VIVORYON THERAPEUTICS
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
VIVORYON THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
1997-01-01
Address:
Halle An Der Saale, Sachsen-Anhalt, Germany
Country:
Germany
Website Url:
http://www.vivoryon.com
Total Employee:
101+
Status:
Active
Total Funding:
188.92 M USD
Technology used in webpage:
SPF LetsEncrypt SSL By Default Font Awesome Apache DMARC All-Inkl All-Inkl DNS Envia TEL
Similar Organizations
AlveoGene
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Akari Therapeutics
Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Kamada
Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique
Krystal Biotech
Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2007-06-25 | Ingenium Pharmaceuticals AG | Ingenium Pharmaceuticals AG acquired by Vivoryon Therapeutics | N/A |
Investors List
Claus Christiansen
Claus Christiansen investment in Post-IPO Equity - Vivoryon Therapeutics
Dawn Biopharma
Dawn Biopharma investment in Post-IPO Equity - Vivoryon Therapeutics
Claus Christiansen
Claus Christiansen investment in Post-IPO Equity - Vivoryon Therapeutics
Biogen
Biogen investment in Venture Round - Vivoryon Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Venture Round - Vivoryon Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Venture Round - Vivoryon Therapeutics
TVM Capital
TVM Capital investment in Venture Round - Vivoryon Therapeutics
Andera Partners
Andera Partners investment in Venture Round - Vivoryon Therapeutics
BB Biotech Ventures
BB Biotech Ventures investment in Venture Round - Vivoryon Therapeutics
IBG Beteiligungsgesellschaft Sachsen-Anhalt
IBG Beteiligungsgesellschaft Sachsen-Anhalt investment in Venture Round - Vivoryon Therapeutics
Official Site Inspections
http://www.vivoryon.com Semrush global rank: 3.41 M Semrush visits lastest month: 4.04 K
- Host name: dd53506.kasserver.com
- IP address: 85.13.129.136
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Vivoryon Therapeutics"
About Us - Vivoryon
Prior to joining Vivoryon, Anne Doering was Director of Investor Relations at BioNTech and Director of Group Strategy at Merck KGaA, where she contributed to the strategic direction of the company. ... He is a business angel and board …See details»
Investors & News - Vivoryon
3 days ago Recent News. Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024; Vivoryon Therapeutics N.V. Presents …See details»
Vivoryon Therapeutics N.V. - LinkedIn
Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients …See details»
Vivoryon Therapeutics - Crunchbase Company Profile …
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of …See details»
Vivoryon Therapeutics NV, VVY:AEX profile - FT.com - Financial …
Nov 8, 2024 Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the …See details»
Vivoryon Therapeutics - VentureRadar
At Vivoryon, we are passionate about creating small molecule medicines to improve the lives of all those who are affected by severe diseases. We build on our in-depth expertise in …See details»
Vivoryon Therapeutics Company Description - Stock Analysis
Nov 7, 2024 Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with …See details»
Our Approach - Vivoryon
At Vivoryon, we are passionate about creating small molecule medicines to improve the lives of all those who are affected by severe diseases. We build on our in-depth expertise in …See details»
Vivoryon Therapeutics - Overview, News & Similar companies
Who is Vivoryon Therapeutics. With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and pr ogression, …See details»
Vivoryon Therapeutics - Craft
Aug 2, 2024 Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age …See details»
Vivoryon Therapeutics NV, 05Y:STU profile - FT.com - Financial Times
5 days ago Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the …See details»
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial ... - BioSpace
4 days ago Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on …See details»
Vivoryon Therapeutics
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, …See details»
Financial Information - Vivoryon
Jun 30, 2024 Publication Date: Publication: Document (pdf) Materials: September 12, 2024: Half Year Results 2024: Interim Management Report June 30, 2024: Press releaseSee details»
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney ...
Oct 1, 2024 Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on …See details»
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial …
Dec 6, 2023 Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress VIVIAD and VIVA-MIND studies both advancing as planned at …See details»
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results …
4 days ago Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - …See details»
Presentations & Webcasts - Vivoryon
Presentation Results 2023 Link to webcast. November 14, 2023 – Jefferies London Healthcare Conference 2023 Link to webcast. October 17, 2023 – Featured presentations and a …See details»
Vivoryon Therapeutics to Unveil Q3 2024 Financial Results
4 days ago Vivoryon Therapeutics, a clinical stage company focused on developing small molecule medicines for modulating pathologically altered proteins, has announced it will …See details»
Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results …
4 days ago Halle (Saale) / Munich, Germany, December 04, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on …See details»